Guilford Gliadel
Executive Summary
Sales force of approximately 25 to 35 reps from Cardinal Health's sales and marketing services subsidiary, formerly MarketForce, will market carmustine wafer following reacquisition of rights from Aventis. Aventis will continue to market the malignant brain cancer treatment until year-end during the transition period
You may also be interested in...
Guilford Seeks To Triple Gliadel Market With First-Line Indication
Approval of Guilford Pharmaceuticals' Gliadel Wafer for first-line treatment of metastatic brain cancer could triple use of the product, the company reported.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011